The FDA has approved an injection in combination with an established oral therapy for the treatment of acute promyelocytic leukemia.
Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.
The growing use of effective treatment strategies for metastatic cancer in the brain has not been documented in certain patient populations.
A recent systematic review analyzed the predictors of emotional distress a year or more after a cancer diagnosis.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
The FDA expanded the approved use of a therapy for metastasized breast cancer with a certain germline genetic mutation.
Elderly lung cancer patients who are black or from less educated communities are less likely to get the combination of chemotherapy and radiation that’s linked to better survival odds.
Two-year post-radiotherapy biopsies do not predict survival for most men with prostate cancer.
The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
Women with breast cancer often feel rushed to make a decision about surgery, and some of them might benefit from more time and better educational materials to inform their treatment choices.